Preet Kaur Gill MP faced the House of Lords Science and Technology Committee on 7 July 2026 defending an NHS innovation record that may not survive the government she serves.

Lords Committee Questions Ministers Who May Not Outlast the Month

There is something almost poignant about watching a government account for its record days before it may cease to exist. On Tuesday 7 July, Preet Kaur Gill MP, Parliamentary Under-Secretary of State for Health Innovation and Safety, sat before the House of Lords Science and Technology Committee alongside Fiona Bride, interim director general for commercial and growth at the Department of Health and Social Care, and Rob Thompson, chief digital, data and technology officer for DHSC and NHS England. Nominations for the Labour leadership contest triggered by Keir Starmer’s resignation open on 9 July, just two days later. Barring a late challenger, Andy Burnham will be prime minister within weeks. The ministers answering for the government’s innovation strategy this week may not be the ones implementing its recommendations by autumn.

That timing matters more than the Committee’s own framing suggests. The inquiry was launched in March to examine, through the lens of personalised medicine and AI, why NHS adoption of Britain’s own life sciences innovations so often stalls before it reaches patients at scale. The government’s flagship data platform deal with Palantir has already become an object lesson in exactly the failure mode this inquiry exists to interrogate, with Integrated Care Boards including Greater Manchester declining to adopt a system they judged inferior to infrastructure they had already built themselves. Fragmentation was not a hypothesis the Committee needed to test. It was sitting in the public record before the ministers had even taken their seats.

A Question the Committee Framed Around Genomics but Meant More Broadly

The Committee’s call for evidence asked what would strengthen the feedback loop between research, industry and the NHS so that domestically developed innovation reaches patients at scale, rather than staying trapped in whichever trust piloted it first. Genomics and CAR T-cell therapy make for a cleaner case study than a care planning app, but the mechanism of failure is identical. NHS England’s £10 billion technology settlement, confirmed only a day before this hearing, buried a Single Patient Record inside its AI triage and ambient notetaking headlines without a word on whether it would extend beyond the NHS’s own boundary into local authority and domiciliary care systems. Rob Thompson’s presence on Tuesday’s panel, in the same digital and data role that oversees that settlement, suggests this Committee session and last week’s funding announcement are one continuous story rather than two.

Why Fragmentation Outlives Any Single Minister

Fiona Bride’s commercial and growth brief speaks to the procurement mechanics that suppliers across health and care technology cite constantly as the practical ceiling on scale, whatever the strength of the clinical evidence behind a product. That ceiling has structural causes that no reshuffle fixes on its own. Integrated Care Boards commission inconsistently against each other. NHS budgets and local authority adult social care budgets under the Care Act 2014 sit in entirely separate financial worlds, so a remote monitoring platform proven in one ICS area can face no funding route two miles over an ICB boundary. Greater Manchester’s own wearable remote monitoring cluster, backed with £11 million in public and commercial funding specifically to bridge NHS and community care delivery from the outset, remains closer to the exception than the rule.

The Burnham Variable

What makes Tuesday’s session more than a routine parliamentary account is who is likely to inherit its conclusions. Andy Burnham has campaigned, since his return to Westminster in June, on a National Care Service that would integrate social care fully into the NHS, funded by a new social care levy. That is not a minor manifesto flourish. If implemented at anything like the scale Burnham has described, it would collapse precisely the commissioning divide this Committee has spent months documenting as the central obstacle to scaling innovation, the split between NHS funding routes and local authority social care budgets that currently forces technology companies to fight two separate battles for every product. Wes Streeting’s endorsement of Burnham, delivered before his own departure from government, described him as a leader who understood integrated care in a way Whitehall officials did not. Whether that understanding survives contact with Treasury orthodoxy on social care spending, which has constrained every government’s ambitions in this area for over a decade, is a different question entirely.

What the Sector Should Actually Watch

The Committee is expected to publish its final report in the coming months, drawing on written and oral evidence gathered since March. Its practical value to social care providers will not lie in whatever headline recommendation it makes about genomics adoption. It will lie in whether the report’s diagnosis of NHS fragmentation is picked up by whichever government exists by the time it is published, and specifically whether Burnham’s National Care Service pledge, if it survives the transition from campaign promise to Treasury negotiation, treats the interoperability gap this Committee has spent four months describing as a founding design problem rather than an afterthought. Every previous parliamentary inquiry into NHS technology has referenced social care in passing and moved on. This is the first one convened at the exact moment a prime ministerial transition makes that omission genuinely correctable.